GPCR-ligand complex structure within 4 months
In collaboration with a major pharma company, leadXpro AG announced today the successful delivery of multiple GPCR structure determination milestones ahead of schedule.
news
Latest developments, partnerships and scientific breakthroughs
leadXpro enters collaboration on cryo-EM based new lead discovery with Bayer
leadXpro AG announced today a collaboration with Bayer AG to enable structure based drug discovery of membrane protein targets, facilitated by single particle cryo-Electron Microscopy (cryo-EM)
PARK INNOVAARE files building application for leadXpro’s future home
Park InnovAARE files building application for leadXpro’s future home
leadXpro and Boehringer Ingelheim collaborate on membrane protein drug target
leadXpro proudly reports a collaboration contract with Boehringer Ingelheim
leadXpro celebrates its first anniversary
LeadXpro takes its place as world leading structure based drug discovery company and celebrates its first anniversary
leadXpro and Paul Scherrer Institute sign agreement on Beam Line at the Swiss Light Source
Agreement with Paul Scherrer Institute on a beam line at the Swiss Light Source SLS
leadXpro at the PSDI conference
Michael Hennig (CEO, leadXpro) will chair and open the session on „Membrane proteins & hot structures“ at the PSDI 2016 conference with a talk on „Extension of structure based drug discovery on membrane proteins, update on recent developments and examples“.
Further development of Serial Crystallography
leadXpro and PSI scientists team up to develop further serial crystallography
Heptares and leadXpro enter collaboration on GPCR biostructure
Heptares and leadXpro enter collaboration on powerful new approaches to GPCR structure determination for drug discovery